Literature DB >> 29661925

Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations.

Michael O Kinney1, James Morrow1, Chris C Patterson2, Ellen Campbell1, Aline Russell3, Henry W Smithson4, Linda Parsons5, Patrick J Morrison6, Rebecca Bromley7,8, Brenda Liggan9, Norman Delanty9, Beth Irwin1, Stephen J Hunt1, John J Craig1.   

Abstract

OBJECTIVES: After 20 years of data collection, pregnancy registers have informed prescribing practice. Various populations show trends for a reduction in valproate prescribing, which is associated with an increased risk of anatomical teratogenesis and neurodevelopmental effects in those exposed in utero. Our aim was to determine if any shifts in prescribing trends have occurred in the UK and Ireland Epilepsy and Pregnancy Register cohort and to assess if there had been any change in the overall major congenital malformation (MCM) rate over time.
METHODS: The UK and Ireland Epilepsy and Pregnancy Register, a prospective, observational, registration and follow-up study established in 1996, was used to determine the changes in antiepileptic drugs (AEDs) utilised during pregnancy and the MCM rate between 1996 and 2016. Linear regression analysis was used to assess changes in AED utilisation, and Poisson regression was used for the analysis of trends in the MCM rates.
RESULTS: Outcome data for 9247 pregnancies showed a stable percentage of monotherapy to polytherapy prescribing habits over time. After Bonferroni correction, statistically significant (p<0.003) changes were found in monotherapy prescribing with increases in lamotrigine and levetiracetam and decreases in valproate and carbamazepine use. Between 1996 and 2016, the total MCM rate showed a 2.1% reduction per year (incidence risk ratio 0.979 (95% CIs 0.956 to 1.002) but Poisson regression analysis showed that this was not statistically significant p=0.08).
CONCLUSION: Significant changes are seen in the prescribing habits in this cohort over 20 years, but a statistically significant change in the MCM rate was not detected. This work should be replicated on a larger scale to determine if significant changes are occurring in the MCM rate, which would allow a robust economic estimate of the benefits of improvements in prescribing practice and the personal effect of such changes. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  epilepsy; neuroepidemiology; obstetrics

Mesh:

Substances:

Year:  2018        PMID: 29661925     DOI: 10.1136/jnnp-2017-317368

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

1.  Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy.

Authors:  Kimford J Meador; Page B Pennell; Ryan C May; Elizabeth Gerard; Laura Kalayjian; Naymee Velez-Ruiz; Patricia Penovich; Jennifer Cavitt; Jaqueline French; Sean Hwang; Alison M Pack; Maria Sam; Eugene Moore; Dominic M Ippolito
Journal:  Epilepsy Behav       Date:  2018-05-03       Impact factor: 2.937

2.  Change in antiepileptic drug prescription patterns for pregnant women with epilepsy over the years: Impact on pregnancy and fetal outcomes.

Authors:  Ramandeep Bansal; Vanita Suri; Seema Chopra; Neelam Aggarwal; Pooja Sikka; Subhas Chandra Saha; Parampreet Singh Kharbanda; Praveen Kumar
Journal:  Indian J Pharmacol       Date:  2019 Mar-Apr       Impact factor: 1.200

3.  Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability.

Authors:  Jill Clayton-Smith; Rebecca Bromley; John Dean; Hubert Journel; Sylvie Odent; Amanda Wood; Janet Williams; Verna Cuthbert; Latha Hackett; Neelo Aslam; Heli Malm; Gregory James; Lena Westbom; Ruth Day; Edmund Ladusans; Adam Jackson; Iain Bruce; Robert Walker; Sangeet Sidhu; Catrina Dyer; Jane Ashworth; Daniel Hindley; Gemma Arca Diaz; Myfanwy Rawson; Peter Turnpenny
Journal:  Orphanet J Rare Dis       Date:  2019-07-19       Impact factor: 4.123

4.  Maternal complications in pregnancy and childbirth for women with epilepsy: Time trends in a nationwide cohort.

Authors:  Kim Christian Danielsson; Nils Erik Gilhus; Ingrid Borthen; Rolv Terje Lie; Nils-Halvdan Morken
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

5.  Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?

Authors:  Luisa Mari; Fabio Placidi; Andrea Romigi; Mario Tombini; Chiara Del Bianco; Martina Ulivi; Claudio Liguori; Natalia Manfredi; Alessandro Castelli; Nicola Biagio Mercuri; Francesca Izzi
Journal:  Neurol Sci       Date:  2021-09-01       Impact factor: 3.307

6.  Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study.

Authors:  Walid Shouman; Joseph A Delaney; Kaarina Kowalec; Marcus Ng; Chelsea Ruth; Jamieson Falk; Christine Leong; Silvia Alessi-Severini; Alekhya Lavu; Payam Peymani; Sherif Eltonsy
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

7.  Valproate utilisation trends among women of childbearing potential in Ireland between 2014 and 2019: A drug utilisation study using interrupted time series.

Authors:  John E Hughes; Niamh Buckley; Yvonne Looney; Sinead Curran; Maeve Mullooly; Kathleen Bennett
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-03-31       Impact factor: 2.732

8.  Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span.

Authors:  Jana E Jones; Miya R Asato; Mesha-Gay Brown; Julia L Doss; Elizabeth A Felton; Jennifer A Kearney; Delia Talos; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-23       Impact factor: 7.500

9.  Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe.

Authors:  Massoud Toussi; Margarita Shlaen; Florence Coste; Hanka de Voogd; Vasilis Dimos; Sigal Kaplan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-11-23       Impact factor: 2.890

10.  Valproic Acid Concentrations in Mothers, Colostrum and Breastfed Infants during the Early Postpartum Period: Comparison with Concentrations Determined during Delivery and in the Mature Milk Period.

Authors:  Ivana Kacirova; Milan Grundmann; Hana Brozmanova
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.